NXP900

· Nuvectis Pharma, Inc.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for NXP900, covering 2026-01-02 to 2026-01-02. Get the full timeline:

Most recent: Clinical Trial Update: Study of NXP900 With Osimertinib in Subjects With Advanced, EGFR-Mutated Non-Small Cell Lung Cancer [Phase 1]